作者
Enrique Chacón,Félix Boria,R. Rajagopalan Iyer,Francesco Fanfani,Mario Malzoni,Petra Bretová,Ana Luzarraga Aznar,Robert Fruscio,Marcin Jędryka,Richárd Tóth,Anna Myriam Perrone,Athanasios Kakkos,Ignacio Cristóbal Quevedo,Luigi Congedo,Vanna Zanagnolo,Sergi Fernández-González,Beatriz Ferro,Fabrice Narducci,T Hovhannisyan,Elif Akşahin,L. M. Cardenas,M Reyes Oliver,Gonzalo Nozaleda,Marta Arnáez,Marcin Misiek,Annamaria Ferrero,F Pain,Janire Zarragoitia,C. Díaz,Lorenzo Ceppi,Shamsi Mehdiyev,Fernando Roldán-Rivas,Alberto Rafael Guijarro‐Campillo,Joana Amengual,Nabil Manzour,Luisa Sánchez‐Lorenzo,Jorge M. Núñez‐Córdoba,Antonio González‐Martín,J. Mínguez,Luis Chiva
摘要
Management of endometrial cancer is advancing, with accurate staging crucial for guiding treatment decisions. Understanding sentinel lymph node (SLN) involvement rates across molecular subgroups is essential. To evaluate SLN involvement in early-stage (International Federation of Gynecology and Obstetrics 2009 I-II) endometrial cancer, considering molecular subtypes and new European Society of Gynaecological Oncology (ESGO) risk classification.